Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Dec 7;15(12):e50112.
doi: 10.7759/cureus.50112. eCollection 2023 Dec.

Tirzepatide-Induced Biphasic Anaphylactic Reaction: A Case Report

Zhexiang He  1 , Agborya N Tabe  1 , Sohaib Rana  1 , Kristy King  1
Affiliations
Case Reports

Tirzepatide-Induced Biphasic Anaphylactic Reaction: A Case Report

Zhexiang He et al. Cureus. .

Abstract

Anaphylaxis is a rapid and severe reaction to a trigger that is characterized by skin, mucosal, and cardiorespiratory changes. A minority of patients exhibit a biphasic anaphylactic reaction (BAR). Tirzepatide is a dual incretin receptor analog approved for the treatment of type 2 diabetes mellitus (T2DM). Allergic reactions to tirzepatide were reported during clinical trials, but none were severe enough to be characterized as an anaphylactic reaction. We describe a case of a BAR to tirzepatide.

Keywords: biphasic anaphylactic reaction; gip-r; glp-1r; tirzepatide; type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Lieberman P, Camargo CA Jr, Bohlke K, Jick H, Miller RL, Sheikh A, Simons FE. Ann Allergy Asthma Immunol. 2006;97:596–602. - PubMed
    1. Making the GRADE in anaphylaxis management: toward recommendations integrating values, preferences, context, and shared decision making. Shaker MS, Oppenheimer J, Wallace DV, et al. Ann Allergy Asthma Immunol. 2020;124:526–535. - PubMed
    1. Biphasic anaphylaxis: a review of the literature and implications for emergency management. Pourmand A, Robinson C, Syed W, Mazer-Amirshahi M. Am J Emerg Med. 2018;36:1480–1485. - PubMed
    1. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Hartman ML, Sanyal AJ, Loomba R, et al. Diabetes Care. 2020;43:1352–1355. - PMC - PubMed
    1. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Coskun T, Sloop KW, Loghin C, et al. Mol Metab. 2018;18:3–14. - PMC - PubMed

Publication types

LinkOut - more resources